IP Library Granted Patent US 8,883,991
Granted Patent B2
US 8,883,991 · App. 13/863,352 · Granted Nov 11, 2014

Methods and reagents for molecular cloning

Inventors: Jonathan Chesnut (Carlsbad, CA); Steward Shuman (New York, NY); Knut Madden (Carlsbad, CA); John Heyman (Vestal, CA); Bennett Robert (Encinitas, CA)
Assignee: Life Technologies Corporation
C12N15/66C12N15/10C12N15/64
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,883,991
App. No.
13/863,352
Granted
Nov 11, 2014
Kind
B2
Abstract

The present invention provides compositions, methods, and kits for covalently linking nucleic acid molecules. The methods include a strand invasion step. For example, a method of covalently linking double stranded (ds) nucleic acid molecules can include contacting a first ds nucleic acid molecule, which has a topoisomerase linked to a 3′ terminus of one end and has a single stranded 5′ overhang at the same end, with a second ds nucleic acid molecule having a blunt end, such that the 5′ overhang can hybridize to a complementary sequence of the blunt end of the second nucleic acid molecule, and the topoisomerase can covalently link the ds nucleic acid molecules. The methods are simpler and more efficient than previous methods for covalently linking nucleic acid sequences, and the compositions and kits facilitate practicing the methods, including methods of directionally linking two or more ds nucleic acid molecules.

Claims (3)

1. A composition, comprising: a) a first ds nucleic acid molecule comprising a first end and a second end, wherein the first end comprises a 5′ overhang and a topoisomerase covalently bound at the 3′ terminus, and b) a second ds nucleic acid molecule comprising a first blunt end and a second end, wherein the first blunt end comprises a first 5′ nucleotide sequence, which is complementary to the first 5′-overhang, and a first 3′ nucleotide sequence complementary to the first 5′ nucleotide sequence.

2. The composition of claim 1 , wherein the first 5′ nucleotide sequence of the first blunt end of the second ds nucleic acid molecule is hybridized to the first 5′ overhang of the first end of the first nucleic acid molecule, and the first 3′ nucleotide sequence of the first blunt end of the second ds nucleic acid molecule is displaced.

3. The composition of claim 1 , wherein the first ds nucleic acid molecule further comprises a second 5′ overhang at the second end, wherein the second end of the second ds nucleic acid molecule further comprises a second 5′ nucleotide sequence, which is complementary to the second 5′ overhang, and a second 3′ nucleotide sequence complementary to the second 5′ nucleotide sequence.

Assignments (2)
MERGER Recorded Jun 19, 2014
From: INVITROGEN CORPORATION
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 033144/0125 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 16, 2013
From: CHESNUT, JONATHAN; MADDEN, KNUT; HEYMAN, JOHN; BENNETT, ROBERT
To: INVITROGEN CORPORATION
Reel/Frame 030803/0497 →
Continuity (6)
Continuation 13205386 · Aug 8, 2011
Continuation 12409326 · Mar 23, 2009
Continuation 11053187 · Feb 7, 2005
Continuation 09935280 · Aug 21, 2001
Provisional Application 60226563 · Aug 21, 2000
Related Publication 20130323797A1 · Dec 5, 2013